DePuy Synthes to showcase latest innovations across comprehensive spine portfolio at IMAST 2024

JNJ Logo

Highlights include launch of next gen posterior thoracolumbar TriALTIS™ Spine System and TriALTIS™ Navigation Enabled Instruments, combining a new portfolio of implants and instrumentation with key enabling technologies

RAYNHAM, Massachusetts (April 9, 2024) – DePuy Synthes, The Orthopaedics Company of Johnson & Johnson* and part of Johnson & Johnson MedTech**, will showcase new innovation and technological advancements across its comprehensive Spine portfolio, including interactive education opportunities and hands-on demonstrations of the company’s latest innovation – the TriALTIS™ Spine System – at the 31st International Meeting on Advance Spine Techniques (IMAST) 2024, taking place from April 10 to 13, 2024 in San Diego, California.

The TriALTIS™ Spine System is a next generation posterior thoracolumbar pedicle screw system that offers a comprehensive implant portfolio and advanced instrumentation designed for integration with enabling technology. Combined with TriALTIS™ Navigation Enabled Instruments, the TriALTIS™ Spine System aims to address unmet clinical needs across complex spine conditions, including degenerative, tumor, trauma and deformity pathologies.  

The TriALTIS™ Spine System was designed around three pillars: technology that enables seamless integration with power and navigation, reliability rooted in the proven legacy of DePuy Synthes Spine implants, and innovation that offers a new development platform and consistent user experience across all indicated pathologies. Both the TriALTIS™ Spine System and TriALTIS™ Navigation Enabled Instruments are now available in the U.S.  

“We are thrilled to officially launch the TriALTIS™ Spine System,” said Russell Powers†, Worldwide President, Spine, DePuy Synthes. “Our dedication to improving patient outcomes and optimizing the surgeon experience is evident in every aspect of this system – from its seamless integration with power and navigation, to its precision in implant placement to drive more efficiency in the operating room. The TriALTIS™ Spine System marks a significant stride in the future of surgical excellence, and we’re excited to continue to pioneer innovation that helps to advance the treatment of complex spine conditions for surgeons and their patients.”

Key workshops and events

DePuy Synthes will host multiple educational workshops and events as part of the 2024 IMAST program, with the opportunity for attendees to hear from leading experts on critical topics. Educational opportunities include:

  • Surgical Techniques Using Multi-Rod Constructs in Complex Reconstruction for Adults on April 11, 2024, from 12:00 – 1:00 p.m. PT. Room: Salon 10. Panelists will include moderator and surgeon expert Munish C. Gupta, M.D. alongside Ioannis Avramis, M.D., Ali A. Baaj, M.D. and Alekos A. Theologis, M.D.
  • Fireside Chat on Next-Gen Spine Surgery: Redefining Enabling Technology on April 12, 2024 from 11:30 a.m. – 12:30 p.m. PT. Room: Salon 1. Panelists will include moderator Eric O. Klineberg, M.D. and surgeon experts Christopher P. Ames, M.D., Jennifer M. Bauer, M.D. and Isador H. Lieberman, M.D.
  • Company-led, in-booth presentations will take place throughout the course of the meeting with DePuy Synthes experts showcasing Spine portfolio highlights, including live product demonstrations and exhibitions of the TriALTIS™ Spine System, as well as the TELIGEN™ System, a technology platform that enables minimally invasive surgical transforaminal lumbar interbody fusion (MIS-TLIF) procedures through digital tools for advanced visualization  and user-centric procedural control.  

IMAST 2024 Meeting attendees can visit DePuy Synthes at Booth #10 or learn more online here. For more information about the DePuy Synthes vision to Keep People Moving and the company’s unwavering commitment to addressing the most complex and challenging procedures in orthopaedic and neurological spine surgery, read more here.


DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS™ Digital Surgery portfolio, are designed to advance patient care while delivering clinical and economic value to healthcare systems worldwide. Building on our proud product innovation and legacy of industry firsts, we are reimagining the orthopaedic landscape with new advancements in medical technologies and digital surgery across the entire continuum of care to Keep People Moving today and tomorrow. For more information, visit


At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized. For more, visit  

Cautions Concerning Forward-Looking Statements  

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding TriALTIS™ Spine System and TELIGEN™ System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes, Inc., Medical Device Business Services, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. None of DePuy Synthes, Inc., Medical Device Business Services, Inc., nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments.  



*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.

**Comprising the surgery, orthopaedics, vision, and interventional solutions businesses within Johnson & Johnson’s MedTech segment.

†Russell Powers is an employee of Medical Device Business Services, Inc.

Please refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions.

© DePuy Synthes 2024. All rights reserved. US_DPS_SPNE_346443